BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 7, 2021
View Archived Issues
Bile acid sequestrant SAR-442357 improves experimental type 2 diabetes and comorbidities
Read More
C3aR is a potential therapeutic target in vascular cognitive impairment
Read More
Jacobio Pharmaceuticals and AbbVie initiate phase I/II study of JAB-3312
Read More
Enrollment commences in phase I study of recombinant IAP SYN-020
Read More
APX-3330 enters phase II development for diabetic retinopathy
Read More
FDA approves new expanded indication for Anavip
Read More
Zydus reports positive phase III data for PegiHep in patients with COVID-19
Read More
First patient dosed in a phase II study of ensovibep for the treatment of COVID-19
Read More
Antibodies could make things worse in neurodegeneration
Read More
Myeloid cells differ in primary and recurrent glioblastoma
Read More
Unnatural Products describes MDM2/4 bispecific inhibitor UNP-1797
Read More
U.S. researchers patent protein kinase inhibitors
Read More
Roche divulges new TLR antagonists
Read More
Cadila Healthcare presents new NLRP3 inflammasome inhibitors
Read More
Japanese investigators identify P2X4 receptor antagonists
Read More
Forevertek Biotechnology and ProMab Biotechnologies divulge MAbs against SLAM family member 7
Read More
Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai
Read More
Dosing begins in phase I study of the bispecific antibody TJ-L-14B/ABL-503
Read More
Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I
Read More
Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS
Read More
An efficient target deconvolution approach based on highly parallelized CRISPR/Cas9 genome editing
Read More
MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones
Read More
Landos' IND for omilancor in eosinophilic esophagitis cleared in U.S.
Read More
Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors
Read More
Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S
Read More
AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection
Read More